- Previous Close
6.05 - Open
6.07 - Bid 4.32 x 200
- Ask 7.33 x 200
- Day's Range
5.68 - 6.07 - 52 Week Range
4.16 - 11.84 - Volume
1,331,780 - Avg. Volume
2,694,098 - Market Cap (intraday)
859.846M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-3.51 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
27.55
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
www.89bio.comRecent News: ETNB
View MorePerformance Overview: ETNB
Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ETNB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ETNB
View MoreValuation Measures
Market Cap
859.85M
Enterprise Value
457.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.15
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.73%
Return on Equity (ttm)
-78.34%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-367.08M
Diluted EPS (ttm)
-3.51
Balance Sheet and Cash Flow
Total Cash (mrq)
439.96M
Total Debt/Equity (mrq)
9.37%
Levered Free Cash Flow (ttm)
-237.77M